'Hard' Brexit And Damage To MHRA's EU Medtech Reg Role Causing UK Concern

Few it seems want the UK MHRA to lose its strong input into EU medtech regulatory affairs. But the UK's brinkmanship on a hard Brexit and refusal to countenance any jurisdiction for the European Court of Justice post-Brexit could spell a severely diminished role for the UK health care regulator in EU matters after March 2019.

As haranguing over the cost of the UK's EU divorce ratchets up ever higher ahead of the next bilateral talks in Brussels in December, more important matters – not just for health care – are being pushed dangerously down the priority list, including the long-term cost of lost and more-expensive business, and the short-term continuity of medical supplies.

Independent European policy analyst Steve Bridges says the anticipated cost of Brexit circulating in the corridors of Brussels Is about €40bn ($47.4bn). (Also see "UK Medtech One Year Post-Brexit...

More from United Kingdom

More from Europe